Chairman of NKCL Bio Group, Shin Dong-Hwa (center left) and the director of Qingdao Orthopaedic Hospital, Dong Xiao-Guang (center right) had signed MOA on 14th January 2020.
NKCL Bio Group is a Korean Bio-company that researches NK Immune Cell Treatment using NK cells. Starting with the construction start ceremony of Korea’s first GMP Automated Cultivation System for NK Immune Cell treatment on 30th December last year, it had laid its foundation for NKCL’s global expansion.
NKCL Bio group had signed MOA with China-TSRH Association whose members include around 500 general and semi-commercial hospitals, and held a MOA signing ceremony with one of the affiliated organizations, Qingdao Orthopeadic Hospital, regarding NK Immune Cell Treatment procedure and the Management of Operation Cooperation. Around 100 NKCL Korean users also had attended the ceremony as well as the chairman of NKCL Bio Group, Shin Dong-Hwa and the director of Qingdao Orthopaedic Hospital, Dong Xiao-Guang. The chairman of NKCL Bio Group, Shin Dong-Hwa had thanked NKCL’s Korean users who came to China to celebrate MOA. He said, “Thank you for celebrating MOA signing. This will be the first step to vastly increase NKCL’s Chinese patients.”.
NKCL Korean users, who visited China in person to celebrate MOA.
After the signing ceremony, NKCL Korean users had seen with their own eyes the system and infrastructure of Qingdao Orthopaedic Hospital where NKCL’s Immune Cell Treatment will firstly be commercialized. Then, they visited Lichang Kangde hospital (李沧康德医院) where the next MOA will be held.
NKCL Korean users are signing autographs on MOA commemorating photo-wall which also acts as a guest book.
Qingdao Orthopaetic Hospital (青岛颐生健中西医结合骨伤医院), located in Qingdao, China, is an orthopedic specialist which had combined eastern and western medical techniques. The hospital is equipped with surgery and operating rooms where acupuncture and rehabilitation are practiced. In the future, this is where pain clinic and arthritis treatment will be held using NKCL’s NK Immune Cell Treatment, and cancer patients will be gathered for treatments.
Dong Xiao-Guang, the director of Qingdao Orthopaedic Hospital (Left) / Shin Dong-Hwa, the chairman of NKCL Bio Group (right)
Through this MOA signing between both companies, NKCL Bio Group has laid the ground work for its global expansion and signaled its advancement into Chinese market with the size of 1.5 billion population, and into Great China Region like Malaysia, Hong Kong, and Singapore. Furthermore, NKCL Bio Group has revealed that this MOA between Korea and China is a starting point of its plan to go beyond Asia, and to expand into U.S. and Europe.